- Home
- MOBX vs XAIR Comparison
MOBX vs XAIR Comparison
Compare MOBX & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOBX
- XAIR
- Stock Information
- Founded
- MOBX 2020
- XAIR 2011
- Country
- MOBX United States
- XAIR United States
- Employees
- MOBX N/A
- XAIR N/A
- Industry
- MOBX
- XAIR Medical/Dental Instruments
- Sector
- MOBX
- XAIR Health Care
- Exchange
- MOBX Nasdaq
- XAIR Nasdaq
- Market Cap
- MOBX 29.9M
- XAIR 34.7M
- IPO Year
- MOBX N/A
- XAIR N/A
- Fundamental
- Price
- MOBX $0.58
- XAIR $0.52
- Analyst Decision
- MOBX
- XAIR Strong Buy
- Analyst Count
- MOBX 0
- XAIR 4
- Target Price
- MOBX N/A
- XAIR $3.67
- AVG Volume (30 Days)
- MOBX 132.8K
- XAIR 617.0K
- Earning Date
- MOBX 11-29-2024
- XAIR 11-11-2024
- Dividend Yield
- MOBX N/A
- XAIR N/A
- EPS Growth
- MOBX N/A
- XAIR N/A
- EPS
- MOBX N/A
- XAIR N/A
- Revenue
- MOBX $3,921,000.00
- XAIR $2,342,000.00
- Revenue This Year
- MOBX N/A
- XAIR $640.47
- Revenue Next Year
- MOBX N/A
- XAIR $286.81
- P/E Ratio
- MOBX N/A
- XAIR N/A
- Revenue Growth
- MOBX 214.69
- XAIR 685.91
- 52 Week Low
- MOBX $0.55
- XAIR $0.30
- 52 Week High
- MOBX $12.50
- XAIR $2.36
- Technical
- Relative Strength Index (RSI)
- MOBX 31.47
- XAIR 56.95
- Support Level
- MOBX $0.60
- XAIR $0.49
- Resistance Level
- MOBX $0.68
- XAIR $0.54
- Average True Range (ATR)
- MOBX 0.07
- XAIR 0.05
- MACD
- MOBX -0.00
- XAIR -0.00
- Stochastic Oscillator
- MOBX 0.00
- XAIR 70.51
About MOBX Mobix Labs Inc.
Mobix Labs Inc is a fabless semiconductor company developing disruptive next generation wireless and connected solutions that are designed to cater to a broad range of applications in markets including 5G infrastructure, satellite communications, automotive, consumer electronics, e-mobility, healthcare, infrastructure and defense.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.